FDA approves Hospira oncology drug

The drug, which is a solution formulation, has been approved in 200mg, 1gm and 2gm with a concentration of 38 mg/ml strength.

The company expects to roll out the drug in September.

The current FDA approval follows the introduction of Hospira‘s lyophilized or freeze-dried formulation, gemcitabine HCL for injection in November 2010.

Hospira president Thomas Moore said the company is excited to offer US pharmacists a solution form of gemcitabine that reduces preparation time.

"Hospira’s generic gemcitabine solution gives the medical community access to a lower-cost, more convenient offering of this key oncology drug," Moore said.